About: Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples
Creator	Haselmann, Verena Neumaier, Michael Costina, Victor Eichner, Romy Gerhards, Catharina »more»
source	Elsevier; Medline; PMC
abstract	Abstract Background For epidemiologic, social and economic reasons, assessment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection prevalence and immunity are important to adapt decisions to current demands. Hence, immunoassays for detection of anti-SARS-CoV-2 antibodies are introduced rapidly without requiring FDA emergency use authorization approval. Thus, evaluation of test performance predominantly relies on laboratories. This study aimed to evaluate the test performance of recently launched commercial immunoassays in serum and plasma samples. Methods 51 serum samples from 26 patients with confirmed SARS-CoV-2 infection after end of quarantine and 25 control patients were analyzed using anti-SARS-CoV-2 IgG immunoassays from Roche, Euroimmun and Epitope to assess diagnostic sensitivity and specificity. 20 matching pairs of serum and plasma samples were included to analyze comparability between different specimens. Results Overall, a diagnostic sensitivity of 92.3%, 96.2-100% and 100% with a respective diagnostic specificity of 100%, 100% and 84-86% for the immunoassays from Roche, Euroimmun and Epitope were determined. In total, 84-96 % of samples were correctly classified as negative and 92.3-95.2% as positive. The level of concordance between plasma- and serum-based testing diverged between the assays (Epitope r2=0.97; Euroimmun r2=0.91; Roche r2=0.76). Conclusions The immunoassays from Euroimmun and Roche revealed a higher specificity than the Epitope assay without a substantial drop of diagnostic sensitivity. Significant differences between plasma- and serum-based testing highlights the need for determination of appropriate cut-offs per specimen type. Hence, there is an urgent need for test harmonization and establishment of quality standards for an appropriate use of COVID-19 serological tests.
has issue date	2020-07-09(xsd:dateTime)
bibo:doi	10.1016/j.cca.2020.07.007
bibo:pmid	32652161
has license	els-covid
sha1sum (hex)	00f5685e354b2e8f549f7c5161362bfb446210c4
schema:url	https://doi.org/10.1016/j.cca.2020.07.007
resource representing a document's title	Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples
has PubMed Central identifier	PMC7343640
has PubMed identifier	32652161
schema:publication	Clin Chim Acta
resource representing a document's body	covid:00f5685e354b2e8f549f7c5161362bfb446210c4#body_text
is schema:about of	named entity 'plasma' named entity 'samples' named entity 'CITE' named entity 'doi' named entity 'samples' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software